7 October 2024 in ACS Biomaterials Science & Engineering
MAMerel J. W. Adjobo-Hermans
Merel J. W. Adjobo-Hermans
Hydroxyapatite nanoparticles (nHA) have gained attention as potential intracellular drug delivery vehicles due to their high binding affinity for various biomolecules and pH-dependent solubility. Yet, the dependence of nHA cytocompatibility on their physicochemical properties remains unclear since numerous studies have revealed starkly contrasting results. These discrepancies may be attributed to differences in size, shape, crystallinity, and aggregation state of nHA, which complicates fundamental understanding of the factors driving nHA cytotoxicity. Here, we hypothesize that nHA cytotoxicity is primarily driven by intracellular calcium levels following the internalization of nHA nanoparticles. By investigating the cytotoxicity of spherical nHA with different crystallinity and dispersity, we find that both lower crystallinity and increased agglomeration of nHA raise cytotoxicity, with nanoparticle agglomeration being the more dominant factor. We show that the internalization of nHA enhances intracellular calcium levels and increases the production of reactive oxygen species (ROS). However, only subtle changes in intracellular calcium are observed, and their physiological relevance remains to be confirmed. In conclusion, we show that nHA agglomeration enhances ROS production and the associated cytotoxicity. These findings provide important guidelines for the future design of nHA-containing formulations for biomedical applications, implying that nHA crystallinity and especially agglomeration should be carefully controlled to optimize biocompatibility and therapeutic efficacy.
1 March 2021 in Materials Today Bio
Ribonucleic acids (small interfering RNA, microRNA, and messenger RNA) have been emerging as a promising new class of therapeutics for bone regeneration. So far, however, research has mostly focused on stability and complexation of these oligonucleotides for systemic delivery. By comparison, delivery of RNA nanocomplexes from biomaterial carriers can facilitate a spatiotemporally controlled local delivery of osteogenic oligonucleotides. This review provides an overview of the state-of-the-art in the design of biomaterials which allow for temporal and spatial control over RNA delivery. We correlate this concept of spatiotemporally controlled RNA delivery to the most relevant events that govern bone regeneration to evaluate to which extent tuning of release kinetics is required. In addition, inspired by the physiological principles of bone regeneration, potential new RNA targets are presented. Finally, considerations for clinical translation and upscaled production are summarized to stimulate the design of clinically relevant RNA-releasing biomaterials.
16 September 2024 in ACS Applied Materials & Interfaces
Local delivery of messenger ribonucleic acid (mRNA) is increasingly being advocated as a promising new strategy to enhance the performance of biomaterials. While extensive research has been dedicated to the complexation of these oligonucleotides into nanoparticles to facilitate systemic delivery, research on developing suitable biomaterial carriers for the local delivery of mRNA is still scarce. So far, mRNA-nanoparticles (mRNA-NPs) are mainly loaded into traditional polymeric hydrogels. Here, we show that calcium phosphate nanoparticles can be used for both reinforcement of nanoparticle-based hydrogels and the complexation of mRNA. mRNA was incorporated into lipid-coated calcium phosphate nanoparticles (LCPs) formulated with a fusogenic ionizable lipid in the outer layer of the lipid coat. Nanocomposites of gelatin and hydroxyapatite nanoparticles were prepared at various ratios. Higher hydroxyapatite nanoparticle content increased the viscoelastic properties of the nanocomposite but did not affect its self-healing ability. Combination of these nanocomposites with peptide, lipid, and the LCP mRNA formulations achieved local mRNA release as demonstrated by protein expression in cells in contact with the biomaterials. The LCP-based formulation was superior to the other formulations by showing less sensitivity to hydroxyapatite and the highest cytocompatibility.
13 March 2026 in SSRN Electronic Journal
Breast and prostate cancer patients are at high risk of developing bone metastasis. Current treatments are insufficient as evidenced by low 5-year survival rates. To address this challenge bifunctional biomaterials offer the opportunity to both kill cancer cells and regenerate bone after tumor resection. To date these novel biomaterials have been investigated in separate in vitro model systems which target either their anti-cancer efficacy or bone-forming capacity. Herein, we synthesize bifunctional hydroxyapatite nanoparticles functionalized with cisplatin (nHAcis) or without (nHA). Using our recently developed 3D bone metastatic spheroid (BMS) co-culture model for bone metastasis we observed that (unfunctionalized) nHA supplementation does not affect cancer cell proliferation or overall metabolic activity, despite lysosomal uptake of nHA. Remarkably, nHAcis does selectively hamper cancer cell growth in these BMS, demonstrating higher efficacy than cisplatin treatment alone without hampering sustained mineral deposition following osteogenic stimulation with culture media. Overall, we conclude that simultaneous evaluation of both anti-cancer and osteostimulative capacities of novel nanosized bifunctional biomaterials within a single 3D co-culture model evidently goes beyond conventional assessment of these biological functionalities in separate models. Evaluating bifunctional biomaterials in appropriate model systems could accelerate their potential clinical use.